Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/9/2025

Management of Platelet Refractoriness

Diagnosis and Initial Management

  • Patients with confirmed alloimmune platelet refractoriness should receive HLA-A and HLA-B matched platelets as first-line therapy, with platelet cross-matching reserved for those who fail HLA-matched products or cannot be HLA-typed 1, 2
  • Require at least two consecutive ABO-compatible platelet transfusions that both produce poor increments 1, 2, 3
  • Measure platelet counts 1 hour post-transfusion to calculate the corrected count increment (CCI) 4
  • Define poor response as CCI <5,000 or absolute increment <2,000/unit of pooled platelets (or <10,000 for apheresis platelets) 2, 3

Distinguishing Immune from Non-Immune Causes

  • Order HLA class I antibody testing on all refractory patients to confirm alloimmunization 1, 2
  • Approximately 90% of alloimmunized patients have anti-HLA antibodies detectable by standard assays 1, 2, 4
  • Non-immune causes that mimic refractoriness include splenomegaly or hypersplenism 7, disseminated intravascular coagulation (DIC) 3, active hemorrhage 7, and drug-induced antibodies 1

Management Algorithm for Confirmed Alloimmune Refractoriness

  • Provide HLA-A and HLA-B matched platelets from typed donor registries 1, 7, 2
  • Success rate: 50-60% of transfusion events produce adequate increments 7, 8
  • Single-antigen mismatches may still produce satisfactory increments in 75% of cases 7, 8
  • For patients who fail HLA-matched platelets, use platelet cross-matching techniques to identify compatible donors 1, 2

Transfusion Strategy for Refractory Patients

  • Transfuse alloimmunized patients ONLY for active bleeding, not prophylactically 7, 8
  • Reserve limited HLA-matched/cross-matched inventory for therapeutic (not prophylactic) indications 7, 8

Prevention Considerations

  • Leukoreduction of blood products reduces HLA alloimmunization rates from 50% to 3-4% in at-risk populations (no reference, as per instructions to ignore [ignore ref])